Effect of sildena l on arterial stiffness and wave re ection

Size: px
Start display at page:

Download "Effect of sildena l on arterial stiffness and wave re ection"

Transcription

1 Effect of sildena l on arterial stiffness and wave re ection Charalambos Vlachopoulos, Kozo Hirata and Michael F O Rourke Abstract: While sildena l (Viagra ) is widely prescribed for erectile dysfunction, its effect on arterial function is not established. The elastic properties of the aorta, as well as the magnitude and timing of wave re ection, are important factors for ef cient performance of the cardiovascular system and have been identi ed as prognosticators of cardiovascular risk. A total of 24 subjects with coronary artery disease, of whom 14 were hypertensives, aged 69 8 years, were studied in a randomized, placebo-controlled, double-blind, cross-over design. Measurements lasted for 3 h after the sildena l intake (50 mg, p.o.) or placebo. Aortic elastic properties were evaluated with carotid-femoral pulse wave velocity; wave re ection was evaluated with augmentation index and augmented pressure of the aortic pressure waveform. Pulse wave velocity decreased signi cantly (by 0.65 m=s, p ˆ 0.005), denoting a decrease in aortic stiffness. Augmentation index and augmented pressure decreased signi cantly (by 4.47% absolute and by 4.01 mmhg; p < and p ˆ 0.001, respectively), denoting a decreased effect of wave re ection from the periphery. Aortic pulse pressure decreased signi cantly (by 6.74 mmhg, p < 0.05). An active effect of the drug on aortic wall appears to contribute to the decrease in pulse wave velocity, although other mechanisms such as a decrease of blood pressure and autonomic re exes could also have contributed. The effect of sildena l lasted throughout the study (3 h), being evident 30 min after drug intake. In conclusion, this study shows, for the rst time, that sildena l has a favorable effect on aortic stiffness and wave re ection in patients with coronary artery disease. This nding may have important implications for cardiovascular performance and exercise capacity during intercourse. Key words: aorta; arterial stiffness; arteries; coronary disease; sildena l Introduction Erectile dysfunction affects up to 30% of men aged years. 1 Sildena l is a highly selective inhibitor of phosphodiesterase type 5, the predominant isoenzyme responsible for the breakdown of cgm P in the corpora cavernosa. By inhibiting cgmp degradation, sildena l allows for improved erectile function and successful sexual intercourse in most men with erectile dysfunction. 2 Erectile dysfunction is particularly common in patients with cardiovascular disease and shares a number of risk factors, including hypertension, older age, diabetes mellitus, hypercholesterolemia and smoking. 1 However, postmarketing data showed temporal association of cardiovascular events with the use of the drug, raising concerns about its safety. Stiffness of the aorta, as well as the magnitude and timing of wave re ection, are important factors for the performance of the cardiovascular system 3 6 and they 7 9 have been identi ed, together with their pathophysiological manifestations (i.e. increased systolic pressure, 10,11 increased pulse pressure and reduced diastolic pressure 11,14 ), as prognosticators of cardiovascular risk. Medical Professorial Unit, St Vincent s Hospital and Clinic, University of N ew South Wales, Sydney, Australia Address for correspondence: Charalambos Vlachopoulos, Kerassoundos 17, Athens 11528, G reece. Tel: ; Fax: ; Arnold 2003 Furthermore, reduction of wave re ection has been associated with improved exercise capacity. 16 Since phosphodiesterase type 5 is widely present throughout the systemic vasculature, 17 we hypothesized that the drug could have a favorable effect on arterial function. In the present study, we investigated the effect of sildena l on arterial stiffness and wave re ection in patients with coronary artery disease. Methods Subjects We studied 24 men (age 69 8 years) with coronary artery disease. In 19 patients, coronary artery disease was de ned angiographically ( ve had single-vessel, 10 had doublevessel, and four had triple-vessel disease). In the remainder, coronary artery disease was de ned clinically and by non-invasive stress testing. F ourteen patients were hypertensive, 15 had hypercholesterolemia, two had diabetes mellitus (one insulin-dependent), and one was a current smoker. The study protocol was approved by the St Vincent s H ospital R esearch Ethics Committee and all subjects gave written informed consent. Study design The study was carried out using a randomized, placebocontrolled, double-blind, cross-over design. Each subject was studied in the morning on 2 days separated with a non- xed interval (mean 16 days) after an overnight fast. One day the subjects received sildena l (Viagra, P zer) = x03vm509ra

2 244 C Vlachopoulos et al and the other, placebo. After baseline measurements, the patients took either 50 mg of sildena l or placebo, and all measurements were repeated at 30, 60, 120, 150 and 180 min after drug intake. Cardiovascular medications were discontinued for 24 h before the study. Background medications included ACE inhibitors (14 patients), -blockers (nine patients), calcium channel blockers (six patients), diuretics (six patients) organic nitrates (one patient), angiotensin receptor blockers (one patient), statins (12 patients) and other hypolipidemic agents (two patients). Evaluation of aortic elastic properties The pulse travels at a higher velocity in a stiff aorta and vice versa. Pulse wave velocity (PWV) is a well-established index of arterial stiffness and a prognosticator of cardiovascular risk. 7,18 22 Carotid femoral PWV was calculated from measurements of pulse transit time and the distance travelled between two recording sites (PWV ˆ distance [meters]=transit time [seconds]), using a validated non-invasive device (Complior, Dupont Medical), which allows on-line pulse wave recording and automatic calculation of PWV. 20 Measurement of wave re ection indices We used a validated, commercially available system (SphygmoCor ; AtCor Medical, Sydney, Australia) 23,24 which employs the principle of applanation tonometry 3,22,25 28 and appropriate acquisition and analysis software for non-invasive recording and analysis of the arterial pulse. The technique has been described in detail previously. 3,22 27 From radial pulse recordings, the central (aortic) arterial pressure was derived with the use of a generalized transfer function which has been shown to give an accurate estimate of the central arterial pressure waveform and its characteristics, 3,23,26,29,30 and by assuming that the mean pressure in the aorta is the same as the mean pressure in the radial artery since there is practically no change in mean pressure along the arterial tree. 3,30 Waveforms of radial pressure were calibrated according to sphygmomanometric systolic and diastolic pressure measured in the brachial artery since there is practically no pressure pulse ampli cation between the brachial and the radial artery. 3 The augmentation index (AIx) and augmented pressure (AP) of the central waveform were measured as indices of wave re ection. 3,22,24,26 29 The pressure waveform recorded at any site of the arterial tree is the sum of the forward traveling waveform generated by pump ejection, and the backward traveling the echo of the incident wave re ected at peripheral sites. The merging point of the incident and the re ected wave can be identi ed on the pressure waveform as an in ection point. 3 AP is the pressure added to the incident wave by the returning re ected one and represents the pressure boost with which the left ventricle must cope and which is caused by wave re ection. The AIx was de ned as the AP divided by pulse pressure and expressed as a percentage. Larger values of AIx indicate increased wave re ection from the periphery and=or earlier return of the re ected wave as a result of increased PWV (due to increased arterial stiffness), and vice versa. Statistical analysis Data are expressed as the mean SEM. Probability values ( p) were derived from two-sided tests, while values less than 0.05 were considered statistically signi cant. Characteristics and resting cardiovascular parameters were compared between the sildena l and placebo sessions using the paired t-test (after controlling for the assumption of normality). Repeated-measures analysis of variance (averaged F) was used to detect statistically signi cant changes in variables within each session separately and between the sildena l and the placebo session (ˆ two drugs [sildena l vs placebo] seven periods [baseline, 30, 60, 90, 120, 150, and 180 min post-drug]). To take into account the potential effect of mean pressure on PWV changes we adjusted for this covariate by using repeatedmeasures analysis of variance-covariance. Calculations were performed with SPSS software, version 10.0 (Chicago, IL, USA) and SAS software (SAS Institute Inc., Cary, NC, USA). Results There were no differences in baseline characteristics between the two sessions (Table 1). Table 1 Baseline characteristics of the study sessions. Sildena l Placebo p-value Heart rate (beats =min) NS Ejection duration (ms) NS Peripheral SP (mmhg) NS Peripheral DP (mmhg) NS Peripheral PP (mmhg) NS Central SP (mmhg) NS Central DP (mmhg) NS Central PP (mmhg) NS Mean pressure a (mmhg) NS Augmentation index (% ) NS Augmented pressure (mmhg) NS Pulse wave velocity (m=s) NS Data are mean SEM. a Mean pressure is considered to be equal in peripheral and central arteries (see text for details). DP, diastolic pressure; PP, pulse pressure; SP, systolic pressure.

3 Arterial stiffness, wave re ection and sildena l 245 Heart rate increased in the sildena l session (maximum at 90 min, by 2.5 beats per min, p < 0.05), whereas there was no change in the placebo session and no drug interaction. Ejection duration remained unchanged during the study both in the sildena l and placebo sessions and there was no signi cant drug interaction as regards this variable. Both radial and aortic systolic pressures decreased in the sildena l session ( p < for both), whereas they increased in the placebo session ( p < for both). There was a signi cant drug interaction for radial ( p < 0.001) and aortic ( p < 0.001) systolic pressure (F igures 1 and 2). Similarly, both radial and aortic diastolic pressures decreased in the sildena l session ( p ˆ for both), whereas they increased in the placebo session ( p < for both). For both radial and aortic diastolic pressure there was a signi cant drug interaction ( p < for both; F igures 1 and 2). R adial pulse pressure decreased ( p < 0.05) in the sildena l session and increased ( p < 0.001) in the placebo session; there was no signi cant drug interaction (Figure 1). Aortic pulse pressure decreased ( p < 0.01) in the sildena l session and increased ( p < 0.001) in the placebo session; the drug interaction was signi cant ( p < 0.05; Figure 2). PWV decreased ( p < 0.05) in the sildena l session and increased ( p < 0.001) in the placebo session. The change in PWV was evident at 30 min and persisted throughout the 3 h of the study. There was signi cant drug interaction as regards PWV ( p ˆ 0.005; Figure 3). The interaction remained signi cant ( p < 0.05) after adjusting for the effect of mean pressure, indicating that an active effect of the drug on aortic wall contributed in aortic stiffness changes. AIx decreased ( p < 0.05) in the sildena l session and increased ( p < 0.01) in the placebo session; the drug interaction was signi cant ( p < 0.001; Figure 3). The Figure 1 Radial systolic, diastolic and pulse pressures in the sildena l and placebo sessions during the study (mean and standard error of measurement); p-values refer to the drug interaction between the two sessions. Figure 2 Aortic systolic, diastolic and pulse pressures in the sildena l and placebo sessions during the study (mean and standard error of measurement); p-values refer to the drug interaction between the two sessions.

4 246 C Vlachopoulos et al Figure 3 PWV (pulse wave velocity), Alx (augmentation index) and AP (augmented pressure) in the sildena l and placebo sessions during the study (mean and standard error of measurement); p-values refer to the drug interaction between the two sessions. change in AIx was evident at 30min, reached a nadir at 60 min and persisted throughout the 3 h of the study. AP decreased ( p < 0.005) in the sildena l session and increased ( p < 0.001) in the placebo session; the drug interaction was signi cant ( p ˆ 0.001; Figure 3). In the subgroup of hypertensive patients (n ˆ 14), the ndings regarding all variables were similar to those of the total study population. Discussion To the best of our knowledge, this is the rst study to demonstrate the effect of sildena l on aortic elastic properties and wave re ection in patients with coronary artery disease. Oral sildena l decreased aortic stiffness and led to decreased wave re ection, with effects evident 30min after administration, and lasting for at least 3 h. M any patients with erectile dysfunction, taking sildena- l, have coronary and=or other cardiovascular disease since the two conditions share a number of common risk factors, including hypertension, older age, diabetes mellitus, hypercholesterolemia and smoking. 1 Post-marketing data have shown a temporal association of coronary events with the use of the drug. Although the true association between these events and the effect of the drug is dif cult to de ne, concerns about its use have persisted. In this study, sildena l produced a bene cial effect on arterial function by reducing aortic stiffness, wave re ection and aortic pulse pressure. In older subjects, such as those studied here, aortic stiffness and early wave re ection increase left ventricular load and myocardial oxygen demands and hinder ventricular function. 3,4 Furthermore, they compromise coronary blood ow and predispose to ischemia. 3,5,27 In addition, by increasing pulse pressure, they increase pulsatile stretch of the arteries leading to mechanical fatigue of their elastic components. Thus, through these mechanisms, stiffening of the aorta and enhanced early wave re ection exert a combined adverse effect on the integrity of the heart and the arteries in older humans. Indeed, increased aortic stiffness, 7,8 enhanced wave re ection, 9 increased systolic pressure, 10,11 pulse pressure (and especially central pulse pressure 15 ), and reduced diastolic pressure, 11,14 have been identi ed as independent components of cardiovascular risk. Our study was conducted in the resting state and extrapolations for other situations should be interpreted with caution. H owever, the results of the present study may have implications for exercise capacity, which is an important parameter for successful sexual intercourse. It has been demonstrated that reduction of wave re ection is associated with improved exercise capacity in elderly patients, 16 and studies 31 have shown improvement in exercise capacity with use of sildena l. Vascular effects of sildena l in humans include dilation of brachial 32 and epicardial coronary arteries, 33 improvement of coronary blood ow reserve in patients with coronary artery disease 34 and improvement in endothelial function. 32,33,35 Furthermore, similarly to our ndings, sildena l reduces wave re ection in hypertensive patients. 36,37 Reduction in wave re ection and part of the reduction in PWV with sildena l can be attributed to dilation of conduit arteries 3 as seen with nitric oxide donors such as nitrates. 38,39 The mechanisms involved in the effects of sildena l on arterial function can be inferred from its pharmacological action as a vasodilator since PD E5 is present throughout the whole systemic vasculature. 17 An activation of autonomic re exes could also have contributed to the changes observed. The non-signi cant drug interaction on heart rate changes, however, indicates that the contribution of these re exes is probably small. Although specially designed methodology 19 is needed in order to distinguish whether the effect of a drug on aortic stiffness is due to changes of the intrinsic properties of the aortic wall or due to changes in blood pressure, insights on the mechanism of action of sildena l can be inferred from our study. Indeed, the fact that PWV changes remained signi cant after adjusting for changes in mean pressure

5 Arterial stiffness, wave re ection and sildena l 247 indicates that, apart from blood pressure lowering, an active effect of the drug on aortic wall appears to contribute to aortic stiffness changes. N evertheless, the importance and the clinical implications of our ndings are valid irrespective of the mechanism involved. Our study has some limitations. The results might not be directly extendable to patients with other characteristics and further studies are warranted. In addition, augmentation indices vary with heart rate. However, this effect of heart rate on AIx has been quanti ed 40 and since ejection duration remained constant despite an increase in heart rate it can be inferred that, at peak effect, the increase of heart rate by 2.4 beats per minute could have accounted for only 0.97% of the total 4.47% decrease in AIx. Since cardiovascular medications were stopped for 24 h, a small interaction of long-acting drugs with sildena l cannot be excluded. Conclusion Sildena l has a bene cial effect on arterial function in patients with coronary artery disease. The effect is explicable on the basis of vascular phosphodiesterase type 5 inhibition. This nding expands our understanding of the overall cardiovascular pro le of sildena l and may have implications for factors affecting cardiovascular performance and exercise capacity during intercourse. Acknowledgements The authors wish to thank D emosthenes Panagiotakos, PhD for his expert statistical advice. Potential con icts of interest: the study was supported by a grant from P zer; Dr M O Rourke is a Director of AtCor Medical, which manufactures systems for pulse wave analysis. References 1 Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildena l in the treatment of erectile dysfunction. N Engl J Med 1998; 338: Nichols WW, O Rourke MF (eds). M cdonald s blood ow in arteries, fourth edition. London: Edward Arnold, 1998: , , , Kelly RP, Tunin R, Kass DA. Effect of reduced aortic compliance in cardiac ef ciency and contractile function of in situ canine left ventricle. Circ Res 1992; 71: Ohtsuka S, Kakihana M, Watanabe H, Sugishita Y. Chronically decreased aortic distensibility causes deterioration of coronary perfusion during increased left ventricular contraction. J Am Coll Cardiol 1994; 24: Stefanadis C, Vlachopoulos C, Tsiamis E et al. Unfavorable effects of passive smoking on aortic function in men. Ann Intern M ed 1998; 128: Blacher J, Asmar R, Djane S, London G, Safar M. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33: Stefanadis C, Dernellis J, Tsiamis E et al. Aortic stiffness is a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. Eur Heart J 2000; 21: London GM, Blacher J, Pannier B, Guerin A, Marchais S, Safar M. Arterial wave re ections and survival in end-stage renal failure. Hypertension 2001; 38: SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAM A 1991; 265: Vlachopoulos C, O Rourke M. Diastolic pressure, systolic pressure, or pulse pressure? Curr Hypertens Rep 2000; 2: Benetos A, Safar M, Rudnichi A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting coronary heart disease? The Framingham Study. Circulation 1999; 100: Safar M, Blacher, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: Chen CH, Nakayama M, Talbot M et al. Verapamil acutely reduces ventricular vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol 1999; 33: Zusman RM, Morales A, Glasser D, Osterloh I. Overall cardiovascular pro le of sildena l citrate. Am J Cardiol 1998; 83: 35C 44C. 18 Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O Rourke MF. Effects of age on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 1983; 68: Stefanadis C, Stratos C, Vlachopoulos C et al. Pressure diameter relationship of the human aorta. A new method of determination by the application of a special ultrasonic dimension catheter. Circulation 1995; 92: Asmar R, Benetos A, Topouchian J et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995; 26: Vlachopoulos C, Hirata K, Stefanadis C, Toutouzas P, O Rourke M. Caffeine increases aortic stiffness in hypertensive patients. Am J Hypertens 2003; 16: Vlachopoulos C, Hirata K, O Rourke M. Effect of caffeine on aortic elastic properties and wave re ection. J Hypertens 2003; 21: Karamanoglu M, O Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 1993; 14: Wilkinson IB, Fuchs SA, Jansen IM et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998; 16: Kelly RP, Hayward C, Ganis J, Daley JE, Avolio AP, O Rourke MF. Non-invasive registration of the arterial pressure pulse waveform using high- delity applanation tonometry. J Vasc M ed Biol 1989; 1: Chen CH, Nevo E, Fetics B et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of a generalised transfer function. Circulation 1997; 95: Vlachopoulos C, O Rourke M. Genesis of the normal and abnormal pulse. Curr Probl Cardiol 2000; 25: Vlachopoulos C, Hirata K, O Rourke M. Pressure-altering agents affect central aortic pressures more than is apparent from upper limb measurements in hypertensive patients: the role of arterial wave re ections. Hypertension 2001; 38: Segers P, Qasem A, De Backer T, Carlier S, Verdonck P, Avolio A. Peripheral oscillatory compliance is associated with aortic augmentation index. Hypertension 2001; 37:

6 248 C Vlachopoulos et al 30 Pauca A, O Rourke M, Kon N. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38: Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildena l effects on exercise, neurohumoral activation, and erectile dysfunction in congestive heart failure. A double-blind, plaebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: Desouza C, Parulkar A, Lumpkin D, Akers D, Fonceca V. Acute and prolonged effects of sildena l on brachial artery ow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: Halcox JPJ, Nour KRA, Zalos G et al. The effect of sildena l on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildena l in men with severe coronary artery disease. N Engl J Med 2000; 342: Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildena l enhances owmediated vasodilatation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: Mahmud A, Hennesy M, Feely J. Effect of sildena l on blood pressure and arterial wave re ection in treated hypertensive men. J Hum Hypertens 2001; 15: Scho eld RS, Edwards DG, Schuler BT et al. Vascular effects of sildena l in hypertensive cardiac transplant patients. Am J Hypertens 2003; 16: Kelly RP, Gibbs HH, O Rourke MF et al. Nitroglycerin has more favorable effect on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J 1990; 11: Yaginuma T, Avolio A, O Rourke M et al. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Cardiovasc Res 1986; 20: Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The in uence of heart rate on augmentation index and central aortic pressure in humans. J Physiol 2000; 525:

Spurious systolic hypertension 143

Spurious systolic hypertension 143 Spurious systolic hypertension in youth Michael F O Rourke a, Charalambos Vlachopoulos a and Robert M Graham b Abstract: Six young men diagnosed with systolic hypertension had normal carotid pressure wave

More information

Blood Pressure 고려대학교 구로병원 심혈관 센터

Blood Pressure 고려대학교 구로병원 심혈관 센터 Central versus Peripheral Blood Pressure 최철웅 고려대학교 구로병원 심혈관 센터 Contents Central Artery vs Peripheral Artery Limitation of Peripheral BP Clinical Implication of Central BP Measurement of Central BP Central

More information

Applanation tonometry has been proposed to assess

Applanation tonometry has been proposed to assess Original article 1037 Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking Luc M. Van Bortel a,b, Elisabeth J. Balkestein a, Janneke J. van der

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias Cardiovascular System & Its Diseases Lecture #4 Heart Failure & Cardiac Arrhythmias Dr. Derek Bowie, Department of Pharmacology & Therapeutics, Room 1317, McIntyre Bldg, McGill University derek.bowie@mcgill.ca

More information

INTRODUCTION TO EECP THERAPY

INTRODUCTION TO EECP THERAPY INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and

More information

Arterial Stiffness, Wave Reflections and Drug Treatment of Hypertension

Arterial Stiffness, Wave Reflections and Drug Treatment of Hypertension Home SVCC Area: English - Español - Português Arterial Stiffness, Wave Reflections and Drug Treatment of Hypertension Michel E. Safar, MD Department of Internal Medicine, Broussais Hospital, Paris, France.

More information

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.

More information

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years

More information

Drug Treatment in Type 2 Diabetes with Hypertension

Drug Treatment in Type 2 Diabetes with Hypertension Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk

More information

Treatment of cardiogenic shock

Treatment of cardiogenic shock ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria

More information

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI

More information

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium sildenafil citrate 20mg tablets (Revatio ) No. (235/06) Pfizer New indication 6 January 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Prevention of Cardiovascular Disease in Children with Diabetes

Prevention of Cardiovascular Disease in Children with Diabetes Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus

More information

Direct Arterial Blood Pressure Monitoring Angel M. Rivera CVT, VTS (ECC) Animal Emergency Center Glendale, WI March 2003

Direct Arterial Blood Pressure Monitoring Angel M. Rivera CVT, VTS (ECC) Animal Emergency Center Glendale, WI March 2003 Direct Arterial Blood Pressure Monitoring Angel M. Rivera CVT, VTS (ECC) Animal Emergency Center Glendale, WI March 2003 Introduction Direct measurement of arterial blood pressure is obtained via a peripheral

More information

Blood Pressure Waveform Analysis, Arterial Elasticity/Vascular Compliance and Pulse Contour Evaluation

Blood Pressure Waveform Analysis, Arterial Elasticity/Vascular Compliance and Pulse Contour Evaluation Bibliography of Abstracts and Published Articles Blood Pressure Waveform Analysis, Arterial Elasticity/Vascular Compliance and Pulse Contour Evaluation The clinical research studies referenced in this

More information

1 Congestive Heart Failure & its Pharmacological Management

1 Congestive Heart Failure & its Pharmacological Management Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Prof. Keith Baker 1 Congestive Heart Failure & its Pharmacological Management Keith Baker, M.D., Ph.D.

More information

Milwaukee School of Engineering Gerrits@msoe.edu. Case Study: Factors that Affect Blood Pressure Instructor Version

Milwaukee School of Engineering Gerrits@msoe.edu. Case Study: Factors that Affect Blood Pressure Instructor Version Case Study: Factors that Affect Blood Pressure Instructor Version Goal This activity (case study and its associated questions) is designed to be a student-centered learning activity relating to the factors

More information

HEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise

HEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise WEEK 3 SUPPLEMENT HEART HEALTH A Beginner s Guide to Cardiovascular Disease HEART FAILURE Heart failure can be defined as the failing (insufficiency) of the heart as a mechanical pump due to either acute

More information

Normal & Abnormal Intracardiac. Lancashire & South Cumbria Cardiac Network

Normal & Abnormal Intracardiac. Lancashire & South Cumbria Cardiac Network Normal & Abnormal Intracardiac Pressures Lancashire & South Cumbria Cardiac Network Principle Pressures recorded from catheter tip Electrical transducer - wheatstone bridge mechanical to electrical waveform

More information

Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women

Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women Maturitas 45 (2003) 293/298 www.elsevier.com/locate/maturitas Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women Sayaka Miura, Eiichi Tanaka, Akiko Mori, Mayumi

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

Pulse wave velocity (PWV) is an index of arterial stiffness

Pulse wave velocity (PWV) is an index of arterial stiffness Heart Rate An Important Confounder of Pulse Wave Velocity Assessment Pierre Lantelme, Christine Mestre, Michel Lievre, Alain Gressard, Hugues Milon Abstract Arterial stiffness is a strong determinant of

More information

INHERIT. The Lancet Diabetes & Endocrinology In press

INHERIT. The Lancet Diabetes & Endocrinology In press INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn

More information

Edwards FloTrac Sensor & Edwards Vigileo Monitor. Measuring Continuous Cardiac Output with the FloTrac Sensor and Vigileo Monitor

Edwards FloTrac Sensor & Edwards Vigileo Monitor. Measuring Continuous Cardiac Output with the FloTrac Sensor and Vigileo Monitor Edwards FloTrac Sensor & Edwards Vigileo Monitor Measuring Continuous Cardiac Output with the FloTrac Sensor and Vigileo Monitor 1 Topics System Configuration Physiological Principles Pulse pressure relationship

More information

Vascular Effects of Caffeine

Vascular Effects of Caffeine Vascular Effects of Caffeine John P. Higgins MD, MBA, MPHIL, FACC, FACP, FAHA, FACSM, FASNC, FSGC Director of Exercise Physiology Memorial Hermann Sports Medicine Institute Chief of Cardiology, Lyndon

More information

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA 1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate

More information

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. Heart Failure EXERCISES Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. ) 1. Heart rate increase is a kind of economic compensation, which should

More information

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.

More information

Normal Intracardiac Pressures. Lancashire & South Cumbria Cardiac Network

Normal Intracardiac Pressures. Lancashire & South Cumbria Cardiac Network Normal Intracardiac Pressures Lancashire & South Cumbria Cardiac Network Principle Pressures recorded from catheter tip Electrical transducer - wheatstone bridge mechanical to electrical waveform display

More information

Can Common Blood Pressure Medications Cause Diabetes?

Can Common Blood Pressure Medications Cause Diabetes? Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of

More information

Exchange solutes and water with cells of the body

Exchange solutes and water with cells of the body Chapter 8 Heart and Blood Vessels Three Types of Blood Vessels Transport Blood Arteries Carry blood away from the heart Transport blood under high pressure Capillaries Exchange solutes and water with cells

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

BLOOD PRESSURE AND EXERCISE

BLOOD PRESSURE AND EXERCISE BLOOD PRESSURE AND EXERCISE Westminster College STANDARDS: 3.1.10A, 3.1.12A Identify the function of subsystems within a larger system; analyze and describe the function, interaction and relationship among

More information

Case Study 6: Management of Hypertension

Case Study 6: Management of Hypertension Case Study 6: Management of Hypertension 2000 Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure.

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure. Management of Acute Left Ventricular Failure Acute left ventricular failure presents as pulmonary oedema due to increased pressure in the pulmonary capillaries. It is important to realise though that left

More information

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea

More information

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

HYPERTENSION ASSOCIATED WITH RENAL DISEASES RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein

More information

How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough?

How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough? How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough? Per Anton Sirnes MD.Phd.FESC Moss, Norway Chair, ESC Council on Cardiology Practice Conflicts

More information

After acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS

After acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS By Deborah Chyun, RN, PhD, Viola Vaccarino, MD, PhD, Jaime Murillo, MD, Lawrence H. Young, MD, and Harlan M. Krumholz,

More information

Cardiovascular Risk in Diabetes

Cardiovascular Risk in Diabetes Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Journal of Hypertension 2004, 22:2285 2293. a Department of Internal Medicine, Bufalini Hospital, Cesena, b Studio

Journal of Hypertension 2004, 22:2285 2293. a Department of Internal Medicine, Bufalini Hospital, Cesena, b Studio Original article 228 Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device Paolo Salvi a, Giuseppe Lio b, Carlos Labat

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Anticoagulants in Atrial Fibrillation

Anticoagulants in Atrial Fibrillation Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives

More information

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney, R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney, Australia Cardiac rehabilitation is an effective and safe

More information

Geriatric Cardiology: Challenges and Strategies

Geriatric Cardiology: Challenges and Strategies Geriatric Cardiology: Challenges and Strategies No financial disclosures Geriatrics -- No Specific Age 'you know it when you see it' Functional Status Polypharmacy Impaired Renal Function Diagnostic Testing:

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

High Blood Pressure and Your Kidneys

High Blood Pressure and Your Kidneys High Blood Pressure and Your Kidneys About 65 million Americans have high blood pressure, but as many as one third or three in 10 don't even know it. There are usually no signs or symptoms that your blood

More information

Blood Pressure & Effects of Exercise Laboratory #3. Assigned reading. Widmaier, et al. Vander s Human Physiology Ch. 12 OBJECTIVES

Blood Pressure & Effects of Exercise Laboratory #3. Assigned reading. Widmaier, et al. Vander s Human Physiology Ch. 12 OBJECTIVES Laboratory #3 Assigned reading Widmaier, et al. Vander s Human Physiology Ch. 12 OBJECTIVES 1) Learn to measure your blood pressure using a sphygomomanometer. 2) Test the effect of exercise and body position

More information

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana PULMONARY HYPERTENSION Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana What is Pulmonary Hypertension? What is normal? Pulmonary artery systolic pressure

More information

Flash, Rocking on others Added value in DCM and CRT. C. Parsai Polyclinique des Fleurs France

Flash, Rocking on others Added value in DCM and CRT. C. Parsai Polyclinique des Fleurs France Flash, Rocking on others Added value in DCM and CRT C. Parsai Polyclinique des Fleurs France Cleland JGF et al. (2007) Nat Clin Pract Cardiovasc Med 4: 90 101 Predicting CRT Response Device Related Patient

More information

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Test Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Heart Failure - Definition European Heart Journal (2008) 29, 2388 2442 Akute Herzinsuffizienz Diagnostik und

More information

Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy.

Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy. Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy. 1 I have a few objectives for this talk. First, we ll review the normal, anticipated chambers

More information

Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back

Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back to the left atria from the left ventricle, blood is pumped

More information

Section Four: Pulmonary Artery Waveform Interpretation

Section Four: Pulmonary Artery Waveform Interpretation Section Four: Pulmonary Artery Waveform Interpretation All hemodynamic pressures and waveforms are generated by pressure changes in the heart caused by myocardial contraction (systole) and relaxation/filling

More information

Microalbuminuria: An increasingly recognized risk factor for CVD

Microalbuminuria: An increasingly recognized risk factor for CVD Microalbuminuria: An increasingly recognized risk factor for CVD Long known to be associated with kidney disease, the importance of protein in the urine is now becoming recognized as a sensitive, accessible

More information

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Septic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident

Septic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident Septic Shock: Pharmacologic Agents for Hemodynamic Support Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident Objectives Define septic shock and briefly review pathophysiology Outline receptor

More information

Heart Pump and Cardiac Cycle. Faisal I. Mohammed, MD, PhD

Heart Pump and Cardiac Cycle. Faisal I. Mohammed, MD, PhD Heart Pump and Cardiac Cycle Faisal I. Mohammed, MD, PhD 1 Objectives To understand the volume, mechanical, pressure and electrical changes during the cardiac cycle To understand the inter-relationship

More information

How should we treat atrial fibrillation in heart failure

How should we treat atrial fibrillation in heart failure Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Drug treatment of elevated blood pressure

Drug treatment of elevated blood pressure Drug treatment of elevated blood pressure Mark Nelson, Professor and Chair, Discipline of General Practice Professorial Research Fellow, and Senior Member, Menzies Research Institute, University of Tasmania,

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Blood Pressure Classification. Blood Pressure Classification

Blood Pressure Classification. Blood Pressure Classification Blood Pressure Classification Blood Pressure Classification BP Classification SBP mmhg DBP mmhg Normal

More information

Blood Pressure. Blood Pressure (mm Hg) pressure exerted by blood against arterial walls. Blood Pressure. Blood Pressure

Blood Pressure. Blood Pressure (mm Hg) pressure exerted by blood against arterial walls. Blood Pressure. Blood Pressure Blood Pressure Blood Pressure (mm Hg) pressure exerted by blood against arterial walls Systolic pressure exerted on arteries during systole Diastolic pressure in arteries during diastole 120/80 Borderline

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

Carefully review the risks and potential, but unproven, benefits of treatment.

Carefully review the risks and potential, but unproven, benefits of treatment. Hypertension This is a consensus guideline for the pharmacological management of hypertension with frailty. This information was developed by the Dalhousie University Academic Detailing Service and the

More information

3 rd Russian-Bavarian Conference on Bio-Medical Engineering

3 rd Russian-Bavarian Conference on Bio-Medical Engineering 3 rd Russian-Bavarian Conference on Bio-Medical Engineering Blood Pressure Estimation based on Pulse Transit Time and Compensation of Vertical Position Dipl.-Inform. Med. Christian Douniama Dipl.-Ing.

More information

OEM MAXNIBP Frequently Asked Questions

OEM MAXNIBP Frequently Asked Questions Frequently Asked Questions Why does the monitor sometimes inflate the BP cuff, then shortly thereafter reinflate the cuff? How will I know if the monitor is experiencing motion artifact during a measurement?

More information

CORRELATION BETWEEN ARTERIAL STIFFNESS INDEX AND ARTERIAL WAVE PATTERN AND INCIDENCE OF STROKE

CORRELATION BETWEEN ARTERIAL STIFFNESS INDEX AND ARTERIAL WAVE PATTERN AND INCIDENCE OF STROKE ORIGINAL ARTICLE CORRELATION BETWEEN ARTERIAL STIFFNESS INDEX AND ARTERIAL WAVE PATTERN AND INCIDENCE OF STROKE Cheuk-Sing Choy 1,2,3, David Yen-Ju Wang 1, Tu-Bin Chu 4,5, Wai-Mau Choi 6 *, Hung-Yi Chiou

More information

Hypertension and Diabetes

Hypertension and Diabetes Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas

More information

Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a

Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II April 2013 Reference : NHS Commissioning Board Clinical Commissioning Policy: Amendment to National Policy

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

An outcomes research perspective on medical education: the predominance of trainee assessment and satisfaction

An outcomes research perspective on medical education: the predominance of trainee assessment and satisfaction Research papers An outcomes research perspective on medical education: the predominance of trainee assessment and satisfaction Jay B Prystowsky 1 & Georges Bordage 2 Context A fundamental premise of medical

More information

Starling s Law Regulation of Myocardial Performance Intrinsic Regulation of Myocardial Performance

Starling s Law Regulation of Myocardial Performance Intrinsic Regulation of Myocardial Performance Regulation of Myocardial Performance Intrinsic Regulation of Myocardial Performance Just as the heart can initiate its own beat in the absence of any nervous or hormonal control, so also can the myocardium

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS - Summary CHRONIC COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS - Epidemiological study - PhD Manager: Professor PhD.

More information

The practice of lowering blood pressure (BP)

The practice of lowering blood pressure (BP) Original Paper Treatment of Hypertension in the Inpatient Setting: Use of Intravenous Labetalol and Hydralazine Alan B. Weder, MD; 1 Steven Erickson, PharmD 2 Acute blood pressure elevations are commonly

More information

Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome

Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual

More information

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Srinivasan Rajagopal M.D. Assistant Professor Division of Cardiothoracic Anesthesia Objectives Describe the pathophysiology

More information

The Canadian Association of Cardiac

The Canadian Association of Cardiac Reinventing Cardiac Rehabilitation Outside of acute care institutions, cardiovascular disease is a chronic, inflammatory process; the reduction or elimination of recurrent acute coronary syndromes is a

More information

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial

More information

Cardiac Catheterization in Patients with Pulmonary Hypertension

Cardiac Catheterization in Patients with Pulmonary Hypertension Cardiac Catheterization in Patients with Pulmonary Hypertension Russel Hirsch, M.D. And James Tarver, M.D. Cincinnati Chldren s Hospital Medical Center And Orlando Heart Center Disclosures Russel Hirsch

More information

MEDICAL THERAPY OF ED Ian Eardley

MEDICAL THERAPY OF ED Ian Eardley MEDICAL THERAPY OF ED Ian Eardley Erectile Dysfunction Plan of treatment Regardless of the aetiology of the ED, most men will benefit from oral therapy. If oral therapy fails, then more invasive options

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

European system for cardiac operative risk evaluation (EuroSCORE) q

European system for cardiac operative risk evaluation (EuroSCORE) q European Journal of Cardio-thoracic Surgery 16 (1999) 9±13 European system for cardiac operative risk evaluation (EuroSCORE) q S.A.M. Nashef*, F. Roques, P. Michel, E. Gauducheau, S. Lemeshow, R. Salamon,

More information

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose Current Management of Atrial Fibrillation Mary Macklin, MSN, APRN Concord Hospital Cardiac Associates DISCLOSURES I have no financial conflicts to disclose Book Women: Fit at Fifty. A Guide to Living Long.

More information

ACSM Risk Factor Identification and Risk Stratification

ACSM Risk Factor Identification and Risk Stratification Thresholds for Use With ACSM Risk Stratification (p 24G) ACSM Risk Factor Identification and Risk Stratification By Dr. Sue Beckham, Ph.D., RCEP, PD Positive Family History Cigarette Smoking Myocardial

More information

CARDIO-VASCULAR SYSTEM MODULE. Academic Year 2004-2005 Study Guide

CARDIO-VASCULAR SYSTEM MODULE. Academic Year 2004-2005 Study Guide CARDIO-VASCULAR SYSTEM MODULE Academic Year 2004-2005 Study Guide CVS Objectives At the end of this part of the course the student should be able to recognize: 1. The histology and ultra-structure of the

More information